SCHEMBL3610207

SCHEMBL3610207

COc1ccc(C)cc1S(=O)(=O)n1ccc2c(CCN)cccc21

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 12/20 0.57
HTR1A P08908 2/20 0.57
HTR1D P28221 2/20 0.57
HTR1B P28222 2/20 0.57
HTR1F P30939 2/20 0.57
HTR7 P34969 2/20 0.57
DRD3 P35462 2/20 0.57
RECQL P46063 1/20 0.48
USP2 O75604 1/20 0.45
GAA P10253 1/20 0.45
KMT2A Q03164 1/20 0.45
FABP4 P15090 2/20 0.44
DRD2 P14416 1/20 0.43
CPT2 P23786 1/20 0.43
CPT1A P50416 1/20 0.43
CPT1B Q92523 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3610205 0.86 RECQL (0.49) HTR6RECQLUSP2GAAKMT2A
SCHEMBL3615066 0.82 HTR6 (0.57) HTR6RECQLUSP2GAAKMT2A
SCHEMBL3620399 0.81 RECQL (0.53) HTR6RECQLUSP2GAAKMT2A
SCHEMBL3623733 0.80 HTR6 (0.68) HTR6
SCHEMBL3620172 0.79 RECQL (0.51) HTR6RECQLUSP2GAAKMT2A
Trifluoroacetic Acid SCHEMBL3618419 0.79 CPT2 (0.47) HTR6RECQLUSP2GAAKMT2A
SCHEMBL3619645 0.78 RECQL (0.50) HTR6RECQLUSP2GAAKMT2A
SCHEMBL3620134 0.78 HTR6 (0.48) HTR6RECQLUSP2GAAKMT2A
SCHEMBL3609032 0.78 TSHR (0.46) HTR6RECQLUSP2GAAKMT2A
SCHEMBL3620928 0.78 HTR6 (0.42) HTR6RECQLUSP2GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046741-B1 INDOLES AS 5-HT6 MODULATORS PROXIMAGEN LTD (GB) 2012-10-31 EP claimed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US claimed
EP-2046741-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (publ) (SE) 2009-04-15 EP claimed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US claimed
WO-2008003703-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO claimed
EP-2046741-B1 INDOLES AS 5-HT6 MODULATORS PROXIMAGEN LTD (GB) 2012-10-31 EP disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032968-A1 New compounds HTR6, HTR1B, HTR1A HTR6 1/4885HTR1A 3/4885HTR1D 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.